Cargando…

Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment

SIMPLE SUMMARY: The detailed role of the TP53 p.P72R (rs1042522) variant in the etiology and course of multiple myeloma (MM), as well as its association with chromosome 17 aberrations, has not been analyzed in a such a wide range. In our study, we have explored the significance of the p.P72R variant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popek-Marciniec, Sylwia, Styk, Wojciech, Wojcierowska-Litwin, Magdalena, Chocholska, Sylwia, Szudy-Szczyrek, Aneta, Samardakiewicz, Marzena, Swiderska-Kolacz, Grazyna, Czerwik-Marcinkowska, Joanna, Zmorzynski, Szymon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571826/ https://www.ncbi.nlm.nih.gov/pubmed/37835441 http://dx.doi.org/10.3390/cancers15194747

Ejemplares similares

The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
por: Popek-Marciniec, Sylwia, et al.
Publicado: (2023)

The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma
por: Zmorzynski, Szymon, et al.
Publicado: (2021)

ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma
por: Zmorzynski, Szymon, et al.
Publicado: (2019)

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma
por: Zmorzyński, Szymon, et al.
Publicado: (2019)

The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma
por: Zmorzyński, S., et al.
Publicado: (2020)

Persistence Is Multi-Trait: Persistence Scale Development and Persistence Perseveration and Perfectionism Questionnaire into Polish Translation
por: Styk, Wojciech, et al.
Publicado: (2023)

Influence of Algae Supplementation on the Concentration of Glutathione and the Activity of Glutathione Enzymes in the Mice Liver and Kidney
por: Świderska-Kołacz, Grażyna, et al.
Publicado: (2021)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

The Effects of Genistein at Different Concentrations on MCF-7 Breast Cancer Cells and BJ Dermal Fibroblasts
por: Pawlicka, Magda Aleksandra, et al.
Publicado: (2022)

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2018)

Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2020)

Significance of Polymorphisms and Expression of Enzyme-Encoding Genes Related to Glutathione in Hematopoietic Cancers and Solid Tumors
por: Zmorzyński, Szymon, et al.
Publicado: (2015)

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2022)

NOTCH3 T6746C and TP53 P72R Polymorphisms Are Associated with the Susceptibility to Diffuse Cutaneous Systemic Sclerosis
por: Zmorzyński, Szymon, et al.
Publicado: (2020)

The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2023)

MON-519 In Silico Analysis of rs1042522 and rs1042522 Polymorphic Variants of TP53 Gene
por: Bó, Izabela Dal, et al.
Publicado: (2020)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease
por: Lin, Q, et al.
Publicado: (2015)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Is body image associated with perseverance? A study among people with normal and increased body weight
por: Styk, Wojciech, et al.
Publicado: (2019)

Is Body Image Associated With Perseverance? A Study Among People With Normal And Increased Body Weight [Response To Letter]
por: Styk, Wojciech, et al.
Publicado: (2019)

Effectiveness of different types of mental simulation in the weight loss process based on a perseverance study among people with different BMI
por: Styk, Wojciech, et al.
Publicado: (2021)

Reliable Knowledge about Obesity Risk, Rather Than Personality, Is Associated with Positive Beliefs towards Obese People: Investigating Attitudes and Beliefs about Obesity, and Validating the Polish Versions of ATOP, BAOP and ORK–10 Scales
por: Styk, Wojciech, et al.
Publicado: (2022)

I Don’t Want to Be Thin! Fear of Weight Change Is Not Just a Fear of Obesity: Research on the Body Mass Anxiety Scale
por: Styk, Wojciech, et al.
Publicado: (2023)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and Perspectives
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2022)

The Genetic Variants of NOTCH3 (6746T>C) and PSMA6 (-8C>G) as Possible Risk Factors of Psoriasis Development
por: Bartosińska, Joanna, et al.
Publicado: (2021)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

TP53 rs1042522 polymorphism and early-onset breast cancer
por: Icen-Taskin, Irmak, et al.
Publicado: (2020)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Pleural Neoplasms—What Could MRI Change?
por: Szczyrek, Michał, et al.
Publicado: (2023)

Aneuploidy among androgenic progeny of hexaploid triticale (XTriticosecale Wittmack)
por: Oleszczuk, Sylwia, et al.
Publicado: (2010)

Association of TP53 rs1042522 G > C, MDM2 rs2279744 T > G, and miR-34b/c rs4938723 T > C polymorphisms with aneuploidy pregnancy susceptibility
por: Chan, Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_61h1aichdjuq7k9p6qchicvktm